Achyut Healthcare Board Greenlights ₹3.48 Cr Preferential Share Sale

Achyut Healthcare Limited plans to raise ₹3.48 crore through a preferential allotment of 58,00,000 equity shares at ₹6 per share. The issue price includes a ₹5 premium.

Investor Insight: Capital raised at a premium, expanding the share base amid margin pressures.

Board Approves Share Sale

Achyut Healthcare Limited's Board of Directors met on March 23, 2026, approving a preferential allotment of 58,00,000 equity shares. The shares are being issued at a premium of ₹5 over the face value of ₹1, setting the issue price at ₹6 per share.

This private placement aims to raise a total of ₹3.48 crore. The allotment is being made to both promoter and non-promoter groups.

Why This Matters

The preferential allotment will enhance Achyut Healthcare's capital base by ₹3.48 crore. This infusion of funds at a premium indicates investor confidence and provides the company with resources that can be deployed for business growth or working capital needs.

Company Background

Incorporated in 1996, Achyut Healthcare is an Ahmedabad-based pharmaceutical company engaged in manufacturing and trading formulations, APIs, and medical devices. The company made its public debut through an IPO in March 2022, raising ₹3.6 crore. It successfully migrated from the BSE SME platform to the BSE Main Board in January 2026.

In recent years, promoter group entities, including Akshit M. Raycha HUF, have been steadily increasing their stakes through open market purchases, signalling continued promoter confidence. The company also underwent a stock split in December 2024, reducing its face value from ₹10 to ₹1.

What Changes Now

• The company's issued, subscribed, and paid-up capital will increase from 23,55,57,000 shares to 24,13,57,000 shares.
• The 58,00,000 newly allotted equity shares will carry identical rights to dividends and voting as existing shares.
• The capital infusion will bolster the company's financial position for future strategic initiatives.

Risks to Watch

• Margin Pressure: Recent quarterly results (Q3 FY26) show a significant profit decline (87% YoY) despite revenue growth, pointing to persistent margin pressures and operational challenges.
• High Debtors: The company has historically recorded high debtors, with figures standing around 160 days.
• Low Profitability Metrics: Achyut Healthcare has demonstrated a low Return on Equity (ROE) and Return on Capital Employed (ROCE) in recent periods.
• Regulatory Vigilance: SEBI has a history of penalizing entities for non-genuine trades and artificial volume generation in illiquid stock options segments on the BSE, reflecting ongoing regulatory oversight of market practices.
• No Dividend Payout: The company has not paid dividends historically.

Peer Comparison

Achyut Healthcare operates in the highly competitive Indian pharmaceutical sector. Its peers include large-cap players like Sun Pharma Industries, Divi's Laboratories, Torrent Pharmaceuticals, and Dr. Reddy's Laboratories, which have significantly larger market capitalizations and broader operational footprints. Achyut Healthcare's market capitalization (around ₹129-136 crore) is substantially smaller, positioning it as a micro-cap entity within this segment.

Key Metrics

• The company's market capitalization was approximately ₹129 crore as of March 2026.
• Promoter holding stood at 47.71% as of December 2025, with an increasing trend from promoter group entities via open market purchases.
• Foreign Institutional Investor (FII) holdings were 5.26% as of December 2025.

What to Track Next

• The deployment of the ₹3.48 crore raised through the preferential allotment and its impact on business growth.
• Future financial performance, particularly improvements in margins and debtor management.
• Any further stake movements or disclosures from promoter group entities.
• Management commentary on growth strategies and capital utilization in future communications.
• The company's ability to scale its operations and compete effectively against larger peers.